A pioneering Merck & Co.-funded study is set to explore the ability of the microbiome to boost immuno-oncology therapy outcomes, and other companies are quickly gearing up to enter this clinical space.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
PowerPoint slides
Rights and permissions
About this article
Cite this article
Mullard, A. Oncologists tap the microbiome in bid to improve immunotherapy outcomes. Nat Rev Drug Discov 17, 153–155 (2018). https://doi.org/10.1038/nrd.2018.19
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd.2018.19
This article is cited by
-
Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications
Signal Transduction and Targeted Therapy (2025)
-
From Gut to Brain: The Impact of Short-Chain Fatty Acids on Brain Cancer
NeuroMolecular Medicine (2025)
-
The link among microbiota, epigenetics, and disease development
Environmental Science and Pollution Research (2021)
-
Exploring the emerging role of the microbiome in cancer immunotherapy
Journal for ImmunoTherapy of Cancer (2019)
-
Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis
Journal of Neuroinflammation (2019)